| First Author | Cui C | Year | 2021 |
| Journal | Cell | Volume | 184 |
| Issue | 12 | Pages | 3163-3177.e21 |
| PubMed ID | 33964209 | Mgi Jnum | J:307143 |
| Mgi Id | MGI:6718725 | Doi | 10.1016/j.cell.2021.04.016 |
| Citation | Cui C, et al. (2021) Neutrophil elastase selectively kills cancer cells and attenuates tumorigenesis. Cell 184(12):3163-3177.e21 |
| abstractText | Cancer cell genetic variability and similarity to host cells have stymied development of broad anti-cancer therapeutics. Our innate immune system evolved to clear genetically diverse pathogens and limit host toxicity; however, whether/how innate immunity can produce similar effects in cancer is unknown. Here, we show that human, but not murine, neutrophils release catalytically active neutrophil elastase (ELANE) to kill many cancer cell types while sparing non-cancer cells. ELANE proteolytically liberates the CD95 death domain, which interacts with histone H1 isoforms to selectively eradicate cancer cells. ELANE attenuates primary tumor growth and produces a CD8(+)T cell-mediated abscopal effect to attack distant metastases. Porcine pancreatic elastase (ELANE homolog) resists tumor-derived protease inhibitors and exhibits markedly improved therapeutic efficacy. Altogether, our studies suggest that ELANE kills genetically diverse cancer cells with minimal toxicity to non-cancer cells, raising the possibility of developing it as a broad anti-cancer therapy. |
